Clinical Trial Update: Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating the safety and efficacy of Grazoprevir and Elbasvir in participants with chronic hepatitis C and chronic kidney disease has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Grazoprevir/Elbasvir

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C Virus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-04-12